Digest Network Come funziona
Network
/
Società
Co
Non verificato

Corcept Therapeutics Incorporated

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

43 comunicati stampa

Guarda tutti i comunicati
06/06/2026
Scienza
Salute
Medicina - Varie
Biotecnologia
Farmaceutica
Sanità
Oncologia
Eventi
Fiere
Industria
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
29/05/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
27/05/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
30/04/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
30/04/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
23/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Fiere
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
10/04/2026
Eventi
Industria
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Farmaceutica
Biotecnologia
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
28/03/2026
Eventi
Cardiologia
Biotecnologia
Farmaceutica
Sanità
Oncologia
Salute
Medicina - Varie
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0
25/03/2026
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Fonte
Corcept Therapeutics Incorporated
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0